Study on retreatment of CHC patients with initial treatment failure
10.3760/cma.j.issn.1003-9279.2012.04.020
- VernacularTitle:慢性丙型肝炎干扰素治疗失败患者的干扰素再治疗研究
- Author:
Lu ZHANG
1
;
Ge SHEN
;
Yan-Li ZHANG
;
Guo-Hua QIU
;
Yao LU
;
Hui ZHAO
;
Min YANG
;
Ming-Hui LI
;
Yao XIE
;
Jun CHENG
;
Dao-Zhen XU
Author Information
1. 首都医科大学附属北京地坛医院
- Keywords:
Hepatitis C,chronic;
Libavirin;
Interferens
- From:
Chinese Journal of Experimental and Clinical Virology
2012;26(4):304-306
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the retreatment of CHC patients with initial treatment failure and how to achieve SVR.Methods 54 patients who had experienced treatment failure were enrolled and retreated with standard treatment of pegylated interferon and ribavirin or intensive treatment,respectively.Their SVR rates were statistically compared,to decide two therapies' application.Results 54 patients had been retreated,and total SVR rate was up to 75.92％,with 88.46％ in relapsed patients and 64.29％ in non-responders.After retreatment with pegylated interferon and ribavirin,SVR rate was 95.45％ in patients with prior interferon monotherapy,and 64.71％ in patients with prior interferon and ribavirin,and 60％ in patients with prior pegylated interferonα-2a monotherapy.SVR rate of relapsed patients was significantly higher than that of non-responders.Conclusions In CHC patients with treatment failure,SVR rate of retreatment with standard treatment or intensive treatment still can be up to 60％-90％.Retreatment with standard therapy can be applied to patients who had received interferon monotherapy or interferon plus ribavirin.Three types of patients who need intensive retreatment were as following:patients nonresponsive to interferon plus ribavirin or pegylated interferon α-2a monotherapy,and patients with treatment failure who had received prior standard treatment.
